Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

496.31 +11.09 (+2.29%)
Delayed Quote Updated: 11:50 AM EDT, Oct 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
77 78 Next >
News headline image
2 Healthcare Stocks to Buy Hand Over Fist in June ↗
They both have pretty impressive pasts, and their prospects look just as bright. 
Via The Motley Fool
News headline image
Alphabet To Rally Over 28%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
News headline image
Healthcare And Biotech Investing: Breakthroughs In The Treatment Of Cancer At ASCO ↗
Healthcare stocks underperformed YTD because of weakness in UNH and strength in Technology and Communication Services. 
Via Talk Markets
News headline image
Cathie Wood Goes Bargain Hunting: 2 Stocks She Just Bought ↗
These companies could generate explosive growth over time. 
Via The Motley Fool
News headline image
Arcturus' Inhaled mRNA Therapeutic In Cystic Fibrosis Study Highlights Potential Amid Competitive Landscape: Analyst ↗
Arcturus Therapeutics shared Phase 1 and Phase 1b trial results for ARCT-032, an inhaled mRNA therapeutic for cystic fibrosis, showing FEV1 improvements and safety . 
Via Benzinga
News headline image
$1000 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
This Is What Whales Are Betting On Vertex Pharmaceuticals ↗
 
Via Benzinga
News headline image
Analyst Expectations For Vertex Pharmaceuticals's Future ↗
 
Via Benzinga
News headline image
Vertex Presents New Data at the European Cystic Fibrosis Conference Demonstrating Significant Benefits of Treatment with TRIKAFTA®
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Large Cap BIopharmaceuticals Overview ↗
As a defensive play healthcare is weighted at about 12% of the S&P 500. 
Via Talk Markets
Topics Stocks
News headline image
3 No-Brainer Stocks to Buy in June ↗
Now is the time to invest in these great stocks. 
Via The Motley Fool
News headline image
5 Top Stocks to Buy in June ↗
This medley of growth, value, and income stocks is poised to thrive long-term, even if the stock market sells off this summer. 
Via The Motley Fool
News headline image
While growth is established for NASDAQ:VRTX, the stock's valuation remains reasonable. ↗
NASDAQ:VRTX is showing decent growth, but is still valued reasonably. 
Via Chartmill
News headline image
2 Biotech Stocks to Buy in May ↗
You could buy these in any month, really. 
Via The Motley Fool
News headline image
Spotlight on Vertex Pharmaceuticals: Analyzing the Surge in Options Activity ↗
 
Via Benzinga
News headline image
S&P 500 Giants Lead Five Healthy Stocks Near Buy Points ↗
Eli Lilly is in a buy zone, while rival Novo Nordisk forged a lower entry. 
Via Investor's Business Daily
Topics Stocks
News headline image
A Very Bullish Reversal Produces A Huge Batch Of Actionable Stocks ↗
It is very hard to get excited about what I'm seeing in the stock market because things have not been the way I've wanted them to be. In this video, I want to show you something as we look at a monthly... 
Via Talk Markets
News headline image
Vertex Stock Recently Hit All-Time High, Leads 8 Top Performers New To IBD Stock Lists ↗
Vertex stock was one of a select group of eight that made it onto IBD top-stocks lists Friday. The big pharma is near its all-time high. 
Via Investor's Business Daily
News headline image
Should Abbott and DexCom Investors Be Worried About Vertex Pharmaceuticals? ↗
Vertex might not present a clear and present danger to Abbott and DexCom but could present a clear future threat. 
Via The Motley Fool
News headline image
Arcturus Therapeutics' Early Cystic Fibrosis Trial Results Encouraging - Analyst Cautiously Optimistic ↗
Arcturus Therapeutics' early Phase 1 results show ARCT-032 is safe and well-tolerated, with promising improvements in lung function. 
Via Benzinga
News headline image
Should you consider NASDAQ:VRTX for quality investing? ↗
VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX) Exhibits Quality Stock Traits. Here's Why. 
Via Chartmill
News headline image
Vertex Pharmaceuticals's Options Frenzy: What You Need to Know ↗
 
Via Benzinga
News headline image
Got $500? 3 Pharma Stocks to Buy and Hold Forever ↗
These players might even beat the market when the conditions are right. 
Via The Motley Fool
News headline image
Is It Too Late to Buy Vertex Pharmaceuticals Stock? ↗
Shares of the growing biotech company have doubled in three years. 
Via The Motley Fool
News headline image
3 High-Flying Stocks That Could Soar Even More ↗
The momentum should continue for Eli Lilly, Novo Nordisk, and Vertex Pharmaceuticals. 
Via The Motley Fool
News headline image
SLB, First Solar And 2 Other Stocks Insiders Are Selling ↗
 
Via Benzinga
News headline image
Walmart, Vertex Pharmaceuticals And More On CNBC's 'Final Trades' ↗
Walmart Inc. reported a "really strong" quarter, with e-commerce sales surging 21%. Adjusted EPS was 60 cents. 
Via Benzinga
News headline image
The 2030 Millionaire’s Club: 3 Biotech Stocks to Buy Now ↗
With interest cuts on the horizon, it's a prime time to consider these high-risk-high-reward biotech stocks to buy. 
Via InvestorPlace
News headline image
Vertex to Participate in Upcoming June Investor Conferences
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Halozyme Therapeutics Stock Earns IBD Stock Rating Upgrade, Hitting 80-Plus RS Rating ↗
On Thursday, biotech Halozyme Therapeutics stock had its Relative Strength (RS) Rating upgraded to 84, up from 80 a day earlier. 
Via Investor's Business Daily
< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
77 78 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.